http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2135881-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d709e3167fa2f99a1803c9cfeb0aca63 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-557 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 |
| filingDate | 1984-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4faad5b889ad04099a26e000349acbc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab44f8da2248893775c05cbf04219f10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_511145895fa97c857403ebad2dc0bc79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb892cd4315824d852c1faa1e380fe56 |
| publicationDate | 1984-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2135881-A |
| titleOfInvention | Method and pharmaceutical compositions for inhibiting or reducing gastrointestinal side effects of non-steroidal anti-inflammatory drugs |
| abstract | Gastrointestinal side effects in mammals during treatment with non-steroidal anti-inflammatory drugs (NSAID) are inhibited or reduced by administering concomitantly or simultaneously a NSAID and a gastrointestinal side-effect-inhibiting or reducing dose of an optically active or racemic prostaglandin or prostacyclin derivative of general formula (I> <IMAGE> wherein a) @, X and W represent, respectively, the C8-C12 substituted monocyclic or C6-C12 substituted bicyclic moiety and the alpha - and the omega - chain of the compounds disclosed in any one of the following patent documents: GB 1,425,961; GB 1,493,557; GB 1,420,338; GB 1,514,542; GB 1,483,880; GB 1,498,105; GB 1,531,567; BE 843,420; GB 1,583,263; GB 1,599,820; GB-B 2,009,145; GB-B 2,086,373; GB-B 2,805872; GB-B 2,013,661 and GB-B 2,025,972, and the pharmaceutically or veterinarily acceptable salts thereof; or b) the meanings of @, X and W are such that the general formula (I) encompasses a compound selected from the group consisting of: PGE1; PGE1, alpha -cyclodextrin clathrate; PGE2, beta -cyclodextrin clathrate; (17S)-17, 20-dimethyl-trans- DELTA <2>-PGE1; 16,16-dimethyl-trans- DELTA <2>-PGE1, methylester; 15(R)-15-methyl-PGE2; (+) (16 RS)-15-deoxy-16-hydroxy-16-methyl-PGE1, methylester; 11-deoxy-11 alpha , 16,16-trimethyl-PGE2; (+)-11 alpha , 16 alpha , beta -dihydroxy-1,9-dioxo-1-(hydroxymethyl)-16-methyl-13-trans-prostene; (+)-4,5-didehydro-16-phenoxy- omega -tetranor-PGE2, methylester; 16,16-dimethyl-PGE2; 4,5,6-trinor-3,7-inter-m-phenylene-3-oxa-PGE1; 11-deoxy-15 epsilon -methyl-PGE1; 19 beta -hydroxy-PGE1; 6 beta -PGI1; 16-phenoxy- omega -tetranor-6 beta -PGI1; 16-m-CF3-phenoxy- omega -tetranor-6 beta -PGI1 and 16-methyl-20-methoxy-PGE2 and, when appropriate, the pharmaceutically or veterinarily acceptable salts thereof. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5601843-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0025771-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-606082-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9116886-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9116895-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0268388-A1 |
| priorityDate | 1983-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 108.